Moffitt logo

Clinical Trials Search

Clinical Trial 19820

Cancer Type: Multiple
Interventions:INCB086550

Study Type: Treatment
Phase of Study: Phase I
Investigators:

  • Solmaz Sahebjam

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Summary

Objective

Primary To determine the safety, tolerability, and DLTs of INCB086550. Secondary To evaluate the PK of INCB086550 in participants with advanced solid tumors. To evaluate the pharmacodynamics of INCB086550 in participants with advanced solid tumors. To determine the preliminary efficacy of INCB086550 in participants with advanced solid tumors. Exploratory To explore biomarkers that predict pharmacologic activity. To evaluate biomarker correlations with clinical safety and early efficacy. To evaluate the efficacy of INCB086550 per iRECIST in participants with advanced solid tumors.

Inclusion Criteria

  • Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1 that are considered nonamenable to surgery or other curative treatments or procedures. Tumor lesions located in a previously irradiated area, or in an area subjected to other loco-regional therapy, are considered measurable if progression has been demonstrated in the lesion.
  • Must have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to or ineligible for standard treatment. There is no limit to the number of prior treatment regimens.
  • Eastern Cooperative Oncology Group performance status score of 0 or 1.
  • Life expectancy > 12 weeks.
  • Willingness to avoid pregnancy or fathering children

  • Exclusion Criteria

  • Laboratory values not within the Protocol-defined range.
  • Clinically significant cardiac disease.
  • History or presence of an ECG that, in the investigator's opinion, is clinically meaningful.
  • Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed. Participants who have previously treated and clinically stable brain or CNS metastases and have not required steroids for at least 7 days before study treatment are eligible.
  • Known additional malignancy that is progressing or requires active treatment.
  • Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.
  • Treatment with anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
  • Active infection requiring systemic therapy.
  • Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
  • Known history of HIV (HIV 1/2 antibodies).
  • Known hypersensitivity or severe reaction to any component of study drug or formulation components